Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma  via  the suppression of YAP

Yu Tian; Bo Tang; Chengye Wang; Deguang Sun; Rixin Zhang; Nan Luo; Zhao Han; Rui Liang; Zhenming Gao; Liming Wang

doi:10.18632/oncotarget.10079

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP

Yu Tian _, Bo Tang, Chengye Wang, Deguang Sun, Rixin Zhang, Nan Luo, Zhao Han, Rui Liang, Zhenming Gao and Liming Wang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:46230-46241. https://doi.org/10.18632/oncotarget.10079

Metrics: PDF 2079 views | HTML 3188 views | ?

Abstract

Yu Tian1, Bo Tang2, Chengye Wang1, Deguang Sun1, Rixin Zhang1, Nan Luo3, Zhao Han1, Rui Liang1, Zhenming Gao1, Liming Wang1

1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China

2Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, P.R. China

3Department of Infection, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China

Correspondence to:

Liming Wang, email: [email protected]

Bo Tang, email: [email protected]

Keywords: metformin, hepatocellular carcinoma, 5-fluorouracil, YAP

Received: March 30, 2016 Accepted: May 29, 2016 Published: June 15, 2016

ABSTRACT

Metformin plays an anti-proliferative role in tumor cells in many types of cancer. However, the correlation between metformin and sensitivity to chemotherapeutic agents in hepatocellular carcinoma (HCC) and the relevant mechanism are unclear. The present study showed that HCC patients with type 2 diabetes mellitus benefited from metformin administration, with a longer overall survival. Metformin resensitized Bel-7402/5-fluorouracil (Bel/Fu) cells to 5-fluorouracil (5-Fu) in vitro and in vivo, and the combination of metformin and 5-Fu inhibited cell proliferation, promoted cell apoptosis and induced G0/G1 cell cycle arrest in the Bel/Fu cells. Moreover, metformin repressed YAP by both decreasing the total protein expression and accelerating the phosphorylation of YAP. The inhibition of YAP subsequently promoted the expression of PTEN, and suppressed the Akt pathway. Therefore, the expression of P-gp and MRP1 was downregulated. Taken together, our findings suggested that metformin may increase sensitivity to chemotherapeutic agents by suppressing YAP in hepatocellular carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10079

Publication Alerts

Research Papers:

Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP

Abstract